An antibody conjugate, Ujvira combines the cancer cell growth–fighting properties of trastuzumab with the cytotoxic capability of emtansine.
Zydus Cadila, an Ahmedabad, India–based pharmaceutical company, said it has launched the world’s first biosimilar form of trastuzumab emtansine, an antibody drug conjugate that not only counteracts cancer cell growth (trastuzumab) but also delivers a cytotoxic agent to the cancer cell and helps to destroy it.
Zydus Cadila said the biosimilar (Ujvira) will be available on the Indian market and can be of value in treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which is highly aggressive and constitutes 20% to 25% of all breast cancers.
“We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment,” said Sharvil Patel, managing director of Cadila Healthcare, in a statement. An estimated 1 in 29 women in India are at risk of developing breast cancer.
In some forms of breast cancer, HER2 receptors are overexpressed on the cancer cell. These receptors receive signals that stimulate the cell to grow and multiply. Trastuzumab attaches to the receptors and blocks the signaling process, causing growth of the cancer cells to stop. Trastuzumab can also alert the immune system to destroy cancer cells.
When trastuzumab attaches to the HER2 receptor, emtansine is able to enter the cancer cell and kill it. The originator trastuzumab emtansine (Kadcycla) was developed by Genentech, a subsidiary of Roche. Zydus Cadila said it would market the biosimilar version “at nearly 80% less than” the originator product.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
March 24th 2025Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.